Transgene to present data on its two therapeutic cancer vaccines at the 2023 ASCO annual meeting
Category: Invir.IO
Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors
Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001
Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer
First patient dosed in Phase I trial evaluating TG6050 15
Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy
H. Le et al.AACR 2023Download the poster herePoster Presentation
PoxSTG, a novel chimeric poxvirus with improved oncolytic potency
P Erbs et al.AACR 2023Download the poster herePoster Presentation
Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators
JB. Marchand et al.AACR 2023Download the poster herePoster Presentation
TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses
JB. Marchand et al.AACR 2023Download the poster herePoster Presentation
Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
Transgene recieves approval to start a Phase I trial of TG6050 15
Transgene announces Financial Calendar for 2023
Transgene announces Financial Calendar for 2023 15
R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
TRANSGENE R&D DAY
